Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study
| Autor: | P.G. Conaghan, Steffen M Jugl, Emma Sullivan, Rieke Alten, Haijun Tian, Atul Deodhar, Vibeke Strand, S Blackburn, K Gandhi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Internationality Ankylosing Spondylitis Psoriatic Arthritis Immunology Pain Work Capacity Evaluation Rheumatoid Arthritis DMARDs (biologic) Osteoarthritis Severity of Illness Index Patient perspective Anti-TNF Knee Osteoarthritis Disability Evaluation Psoriatic arthritis Rheumatology Quality of life Early Rheumatoid Arthritis Surveys and Questionnaires medicine Corticosteroids DAS28 Humans Immunology and Allergy In patient Patient Reported Outcome Measures Fatigue Pain Measurement Ankylosing spondylitis business.industry Incidence (epidemiology) Arthritis Psoriatic Middle Aged medicine.disease Treatment Treatment Outcome Outcomes research Rheumatoid arthritis Quality of Life Physical therapy Female Tumor Necrosis Factor Inhibitors business |
| Zdroj: | RMD Open |
| ISSN: | 2056-5933 |
| Popis: | Background/ObjectiveThe incidence of pain and/or fatigue in people with psoriatic arthritis (PsA) is associated with reduced health-related quality of life (HRQoL) and the ability to work, despite modern advanced therapeutic approaches. This real-world, international study examined these relationships in patients with PsA treated with tumour necrosis factor inhibitors (TNFi).MethodsData from 13 countries were analysed. Patients with PsA and their physicians completed questionnaires capturing demographics, current therapy, current disease status, HRQoL and work status via Medical Outcomes Study 36-Item Short-Form version 2 (SF-36v2), 3-level 5-dimension EuroQoL questionnaire, Health Assessment Questionnaire Disability Index, and Work Productivity and Activity Impairment (WPAI) questionnaire.Results640 patients with PsA were included who had been receiving TNFi for ≥3 months and had completed SF-36v2 bodily pain and vitality domains. Of these, 33.1%, 29.2% and 37.7% of patients reported no, moderate and severe pain, respectively, and 31.9%, 22.5% and 45.6% of patients reported low, moderate and severe fatigue, respectively. Scores across HRQoL variables and WPAI were significantly different across pain and fatigue cohorts (all pConclusionsDespite treatment with biologic agents such as TNFi, data from this global study demonstrated that substantial pain and/or fatigue persist in patients with PsA and that these are significantly associated with reduced HRQoL, physical function and work productivity. These findings suggest that there is an unmet need for additional PsA therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|